Abstract

Mini Review

HIV-1 Immune evasion: The main obstacle toward a successful vaccine

Amitis Ramezani*, Mona Sadat Larijani and Seyed Mehdi Sadat

Published: 19 December, 2018 | Volume 2 - Issue 1 | Pages: 013-015

It is estimated that there are 36.9 million individuals living with HIV-1 from who 21.7 million patients receiving antiretroviral therapy (ART) [1,2]. ART has had a significant effect on the patients’ quality of life recently, however, its global coverage declines to 16-35% in low or middle income parts of Africa [3]. ART is unable to eliminate the virus from the infected individuals despite the fact of great impact on virus life cycle. There is no doubt that vaccination is considered as the most important medical strategy to prevent and suppress the infectious diseases. Nevertheless, there are many difficulties toward the cure or prevention of HIV-1 including the virus characteristics, lack of ideal animal model and funding [4-7].

Read Full Article HTML DOI: 10.29328/journal.aaai.1001013 Cite this Article Read Full Article PDF

References

  1. HIV/AIDS fact sheet: World Health Organization 2017; Ref.: https://goo.gl/8Wuxhk
  2. Sidibé M. UNAIDS DATA 2017. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2017; Ref.: https://goo.gl/U7641S
  3. Barry SM, Lora AJM, Novak RM. Trial, Error, and Breakthrough: A Review of HIV Vaccine Development. AIDS Clin Res. 2014; 5: 359. Ref.: https://goo.gl/4pPrLz
  4. Hütter G ND, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360: 692-698. Ref.: https://goo.gl/E4qunw
  5. Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008; 359:1965-1966. Ref.: https://goo.gl/FgT14G
  6. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100: 4144-4149. Ref.: https://goo.gl/89SNDg
  7. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68: 4650-4655. Ref.: https://goo.gl/FHYMRv
  8. Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet. 2014; 384: 258-271. Ref.: https://goo.gl/4HvPZ4
  9. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013; 339: 966-971. Ref.: https://goo.gl/TJe3n3
  10. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Nat Med 1999; 5: 512-517. Ref.: https://goo.gl/bVadxx
  11. Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, et al. Immune correlates of vaccine protection against HIV-1 acquisition. Sci Transl Med. 2015; 7: 310. Ref.: https://goo.gl/RRWWRe
  12. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature. 2011; 473: 463-469. Ref.: https://goo.gl/76NKfh
  13. Hearps AC, Jans DA. Regulating the functions of the HIV-1 matrix protein. AIDS research and human retroviruses. 2007; 23: 341-346. Ref.: https://goo.gl/fjrqG6
  14. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annual review of biochemistry. 1998; 67: 1-25. Ref.: https://goo.gl/UnKhha
  15. Rolland M. HIV-1 immune evasion-a threat to effective vaccines? Nat Med. 2016; 7; 22: 580-581. Ref.: https://goo.gl/WVjzVr
  16. Malim MH, Emerman M. HIV-1 accessory proteinsensuring viral survival in a hostile environment. Cell Host and Microbe. 2008; 3: 388–398. Ref.: https://goo.gl/fK2mhV
  17. Guha D, Ayyavoo V. Innate Immune Evasion Strategies by Human Immunodeficiency Virus Type 1. Hindawi Publishing Corporation. 2013: 1-10. Ref.: https://goo.gl/cz7kgs
  18. Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, et al. A novelmembrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994; 84: 1922–1930,. Ref.: https://goo.gl/HDsvqL
  19. McMichael AJ1, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews Immunology Letters. 2010; 10: 11-23. Ref.: https://goo.gl/FX6jxc
  20. Agrati C1, D'Offizi G, Gougeon ML, Malkovsky M, Sacchi A, et al. Innate gamma/delta T-cells during HIV infection: terra relatively incognita in novel vaccination strategies? AIDS Reviews. 2011; 13: 3–12. Ref.: https://goo.gl/KpPjM4
  21. Keele BF1, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008; 105: 7552–7557. Ref.: https://goo.gl/hQko8y
  22. Zhang Y, Li J, Li Q. Immune Evasion of Enteroviruses Under Innate Immune Monitoring. Front Microbiol. 2018; 14; 9: 1866. Ref.: https://goo.gl/zyUEjs
  23. Ringel O, Vieillard V, Debré P, Eichler J, Büning H, et al. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. Viruses. 2018; 15: 10. E197. Ref.: https://goo.gl/opGgDn

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More